BS_AKRHBPNZ
Ganglioglioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Ganglioglioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Ganglioglioma
- age_years
- 7.441
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.469
- MYOGENESIS+0.393
- BILE_ACID_METABOLISM+0.342
- PANCREAS_BETA_CELLS+0.302
- XENOBIOTIC_METABOLISM+0.242
- HEDGEHOG_SIGNALING+0.206
- ESTROGEN_RESPONSE_EARLY+0.205
- APICAL_SURFACE+0.163
- KRAS_SIGNALING_UP+0.156
- COAGULATION+0.122
Top 10 suppressed
- MYC_TARGETS_V1-0.742
- MYC_TARGETS_V2-0.660
- E2F_TARGETS-0.648
- G2M_CHECKPOINT-0.619
- UNFOLDED_PROTEIN_RESPONSE-0.615
- PROTEIN_SECRETION-0.548
- DNA_REPAIR-0.546
- MTORC1_SIGNALING-0.424
- MITOTIC_SPINDLE-0.423
- TGF_BETA_SIGNALING-0.414
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_912NX4Y0 | Ganglioglioma | — | 0.957 |
| 2 | SRR1333352 | GTEX | — | 0.940 |
| 3 | BS_QV51J756 | Ganglioglioma | — | 0.940 |
| 4 | SRR1472323 | GTEX | — | 0.937 |
| 5 | SRR1323174 | GTEX | — | 0.936 |
| 6 | MNG768 | — | — | 0.933 |
| 7 | SRR1381673 | GTEX | — | 0.927 |
| 8 | TCGA-62-8397-01A-11R-2326-07 | — | cohortA1 | 0.926 |
| 9 | BS_ZR96A4FH | DNET | — | 0.924 |
| 10 | BS_398KYV92 | Meningioma | — | 0.922 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.469 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.393 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.342 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.302 | Cobimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.242 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.206 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.205 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.163 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.156 | Inavolisib | — uncovered |
| COAGULATION | 0.122 | Binimetinib | — uncovered |
| APICAL_JUNCTION | 0.121 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.093 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.078 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.075 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.060 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.055 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.042 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.015 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.012 | Idelalisib | — uncovered |